A Phase 1 Bioequivalence Study of Naltrexone SR/Bupropion SR Combination Trilayer Tablets From Two Manufacturers in Healthy Subjects
Latest Information Update: 14 Jan 2020
At a glance
- Drugs Naltrexone/bupropion (Primary)
- Indications Obesity
- Focus Pharmacokinetics
- Sponsors Orexigen Therapeutics [CEASED]
- 10 Dec 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov
- 10 Oct 2014 New trial record